HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana
Identifieur interne : 000486 ( Pmc/Corpus ); précédent : 000485; suivant : 000487HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana
Auteurs : Nicholas I. Nii-Trebi ; Shiro Ibe ; Jacob S. Barnor ; Koichi Ishikawa ; James A. M. Brandful ; Sampson B. Ofori ; Shoji Yamaoka ; William K. Ampofo ; Wataru SugiuraSource :
- PLoS ONE [ 1932-6203 ] ; 2013.
Abstract
Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.
Samples were collected from 101 HIV-1-infected patients (32 ART-experienced cases with virological failure and 69 newly diagnosed ART-naïve cases, including 11 children), in Koforidua, Eastern region of Ghana, from February 2009 to January 2010. The
The most prevalent HIV-1 subtype was CRF02_AG (66.3%, 67/101) followed by unique recombinant forms (25.7%, 26/101). Among 31 ART-experienced adults, 22 (71.0%) possessed at least one drug-resistance mutation, and 14 (45.2%) had two-class-resistance to nucleoside and non-nucleoside reverse-transcriptase inhibitors used in their first ART regimen. Importantly, the number of accumulated mutations clearly correlated with the duration of ART. The most prevalent mutation was lamivudine-resistance M184V (
Despite expanding accessibility to ART in Eastern Ghana, the prevalence of transmitted HIV-1 drug resistance presently appears to be low. As ART provision with limited options is scaled up nationwide in Ghana, careful monitoring of transmitted HIV-1 drug resistance is necessary.
Url:
DOI: 10.1371/journal.pone.0071972
PubMed: 23977189
PubMed Central: 3747072
Links to Exploration step
PMC:3747072Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana</title><author><name sortKey="Nii Trebi, Nicholas I" sort="Nii Trebi, Nicholas I" uniqKey="Nii Trebi N" first="Nicholas I." last="Nii-Trebi">Nicholas I. Nii-Trebi</name><affiliation><nlm:aff id="aff1"><addr-line>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ibe, Shiro" sort="Ibe, Shiro" uniqKey="Ibe S" first="Shiro" last="Ibe">Shiro Ibe</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Infection and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Barnor, Jacob S" sort="Barnor, Jacob S" uniqKey="Barnor J" first="Jacob S." last="Barnor">Jacob S. Barnor</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ishikawa, Koichi" sort="Ishikawa, Koichi" uniqKey="Ishikawa K" first="Koichi" last="Ishikawa">Koichi Ishikawa</name><affiliation><nlm:aff id="aff4"><addr-line>AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Brandful, James A M" sort="Brandful, James A M" uniqKey="Brandful J" first="James A. M." last="Brandful">James A. M. Brandful</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ofori, Sampson B" sort="Ofori, Sampson B" uniqKey="Ofori S" first="Sampson B." last="Ofori">Sampson B. Ofori</name><affiliation><nlm:aff id="aff5"><addr-line>Department of Medicine, Koforidua Regional Hospital, Koforidua, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name><affiliation><nlm:aff id="aff6"><addr-line>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ampofo, William K" sort="Ampofo, William K" uniqKey="Ampofo W" first="William K." last="Ampofo">William K. Ampofo</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Infection and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff7"><addr-line>Department of AIDS Research, Nagoya University Graduate School of Medicine, Nagoya, Japan</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23977189</idno><idno type="pmc">3747072</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747072</idno><idno type="RBID">PMC:3747072</idno><idno type="doi">10.1371/journal.pone.0071972</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000486</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000486</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana</title><author><name sortKey="Nii Trebi, Nicholas I" sort="Nii Trebi, Nicholas I" uniqKey="Nii Trebi N" first="Nicholas I." last="Nii-Trebi">Nicholas I. Nii-Trebi</name><affiliation><nlm:aff id="aff1"><addr-line>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ibe, Shiro" sort="Ibe, Shiro" uniqKey="Ibe S" first="Shiro" last="Ibe">Shiro Ibe</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Infection and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Barnor, Jacob S" sort="Barnor, Jacob S" uniqKey="Barnor J" first="Jacob S." last="Barnor">Jacob S. Barnor</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ishikawa, Koichi" sort="Ishikawa, Koichi" uniqKey="Ishikawa K" first="Koichi" last="Ishikawa">Koichi Ishikawa</name><affiliation><nlm:aff id="aff4"><addr-line>AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Brandful, James A M" sort="Brandful, James A M" uniqKey="Brandful J" first="James A. M." last="Brandful">James A. M. Brandful</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ofori, Sampson B" sort="Ofori, Sampson B" uniqKey="Ofori S" first="Sampson B." last="Ofori">Sampson B. Ofori</name><affiliation><nlm:aff id="aff5"><addr-line>Department of Medicine, Koforidua Regional Hospital, Koforidua, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name><affiliation><nlm:aff id="aff6"><addr-line>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ampofo, William K" sort="Ampofo, William K" uniqKey="Ampofo W" first="William K." last="Ampofo">William K. Ampofo</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Infection and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff7"><addr-line>Department of AIDS Research, Nagoya University Graduate School of Medicine, Nagoya, Japan</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.</p></sec><sec><title>Methods</title><p>Samples were collected from 101 HIV-1-infected patients (32 ART-experienced cases with virological failure and 69 newly diagnosed ART-naïve cases, including 11 children), in Koforidua, Eastern region of Ghana, from February 2009 to January 2010. The <italic>pol</italic> gene sequences were analyzed by in-house HIV-1 drug-resistance testing.</p></sec><sec><title>Results</title><p>The most prevalent HIV-1 subtype was CRF02_AG (66.3%, 67/101) followed by unique recombinant forms (25.7%, 26/101). Among 31 ART-experienced adults, 22 (71.0%) possessed at least one drug-resistance mutation, and 14 (45.2%) had two-class-resistance to nucleoside and non-nucleoside reverse-transcriptase inhibitors used in their first ART regimen. Importantly, the number of accumulated mutations clearly correlated with the duration of ART. The most prevalent mutation was lamivudine-resistance M184V (<italic>n</italic> = 12, 38.7%) followed by efavirenz/nevirapine-resistance K103N (<italic>n</italic> = 9, 29.0%), and zidovudine/stavudine-resistance T215Y/F (<italic>n</italic> = 6, 19.4%). Within the viral protease, the major nelfinavir-resistance mutation L90M was found in one case. No transmitted HIV-1 drug-resistance mutation was found in 59 ART-naïve adults, but K103N and G190S mutations were observed in one ART-naïve child.</p></sec><sec><title>Conclusions</title><p>Despite expanding accessibility to ART in Eastern Ghana, the prevalence of transmitted HIV-1 drug resistance presently appears to be low. As ART provision with limited options is scaled up nationwide in Ghana, careful monitoring of transmitted HIV-1 drug resistance is necessary.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Frentz, D" uniqKey="Frentz D">D Frentz</name></author><author><name sortKey="Boucher, Cab" uniqKey="Boucher C">CAB Boucher</name></author><author><name sortKey="Van De Vijver, Damc" uniqKey="Van De Vijver D">DAMC van de Vijver</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sagoe, Kwc" uniqKey="Sagoe K">KWC Sagoe</name></author><author><name sortKey="Dwidar, M" uniqKey="Dwidar M">M Dwidar</name></author><author><name sortKey="Lartey, M" uniqKey="Lartey M">M Lartey</name></author><author><name sortKey="Boamah, I" uniqKey="Boamah I">I Boamah</name></author><author><name sortKey="Agyei, Aa" uniqKey="Agyei A">AA Agyei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Delgado, E" uniqKey="Delgado E">E Delgado</name></author><author><name sortKey="Ampofo, Wk" uniqKey="Ampofo W">WK Ampofo</name></author><author><name sortKey="Sierra, M" uniqKey="Sierra M">M Sierra</name></author><author><name sortKey="Torpey, K" uniqKey="Torpey K">K Torpey</name></author><author><name sortKey="Perez Lvarez, L" uniqKey="Perez Lvarez L">L Pérez-Álvarez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ampofo, Wk" uniqKey="Ampofo W">WK Ampofo</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chiba Mizutani, T" uniqKey="Chiba Mizutani T">T Chiba-Mizutani</name></author><author><name sortKey="Miura, H" uniqKey="Miura H">H Miura</name></author><author><name sortKey="Matsuda, M" uniqKey="Matsuda M">M Matsuda</name></author><author><name sortKey="Matsuda, Z" uniqKey="Matsuda Z">Z Matsuda</name></author><author><name sortKey="Yokomaku, Y" uniqKey="Yokomaku Y">Y Yokomaku</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, Va" uniqKey="Johnson V">VA Johnson</name></author><author><name sortKey="Calvez, V" uniqKey="Calvez V">V Calvez</name></author><author><name sortKey="Gunthard, Hf" uniqKey="Gunthard H">HF Gunthard</name></author><author><name sortKey="Paredes, R" uniqKey="Paredes R">R Paredes</name></author><author><name sortKey="Pillay, D" uniqKey="Pillay D">D Pillay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bennett, De" uniqKey="Bennett D">DE Bennett</name></author><author><name sortKey="Camacho, Rj" uniqKey="Camacho R">RJ Camacho</name></author><author><name sortKey="Otelea, D" uniqKey="Otelea D">D Otelea</name></author><author><name sortKey="Kuritzkes, Dr" uniqKey="Kuritzkes D">DR Kuritzkes</name></author><author><name sortKey="Fleury, H" uniqKey="Fleury H">H Fleury</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meloni, St" uniqKey="Meloni S">ST Meloni</name></author><author><name sortKey="Kim, B" uniqKey="Kim B">B Kim</name></author><author><name sortKey="Sankale, J L" uniqKey="Sankale J">J-L Sankalé</name></author><author><name sortKey="Hamel, Dj" uniqKey="Hamel D">DJ Hamel</name></author><author><name sortKey="Tovanabutra, S" uniqKey="Tovanabutra S">S Tovanabutra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vidal, N" uniqKey="Vidal N">N Vidal</name></author><author><name sortKey="Mulanga, C" uniqKey="Mulanga C">C Mulanga</name></author><author><name sortKey="Bazepeo, Se" uniqKey="Bazepeo S">SE Bazepeo</name></author><author><name sortKey="Lepira, F" uniqKey="Lepira F">F Lepira</name></author><author><name sortKey="Delaporte, E" uniqKey="Delaporte E">E Delaporte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tamura, K" uniqKey="Tamura K">K Tamura</name></author><author><name sortKey="Peterson, D" uniqKey="Peterson D">D Peterson</name></author><author><name sortKey="Peterson, N" uniqKey="Peterson N">N Peterson</name></author><author><name sortKey="Stecher, G" uniqKey="Stecher G">G Stecher</name></author><author><name sortKey="Nei, M" uniqKey="Nei M">M Nei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lole, Ks" uniqKey="Lole K">KS Lole</name></author><author><name sortKey="Bollinger, Rc" uniqKey="Bollinger R">RC Bollinger</name></author><author><name sortKey="Paranjape, Rs" uniqKey="Paranjape R">RS Paranjape</name></author><author><name sortKey="Gadkari, D" uniqKey="Gadkari D">D Gadkari</name></author><author><name sortKey="Kulkarni, Ss" uniqKey="Kulkarni S">SS Kulkarni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fischetti, L" uniqKey="Fischetti L">L Fischetti</name></author><author><name sortKey="Opare Sem, O" uniqKey="Opare Sem O">O Opare-Sem</name></author><author><name sortKey="Candotti, D" uniqKey="Candotti D">D Candotti</name></author><author><name sortKey="Sarkodie, F" uniqKey="Sarkodie F">F Sarkodie</name></author><author><name sortKey="Lee, H" uniqKey="Lee H">H Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barth, Re" uniqKey="Barth R">RE Barth</name></author><author><name sortKey="Van Der Loeff, Mfs" uniqKey="Van Der Loeff M">MFS van der Loeff</name></author><author><name sortKey="Schuurman, R" uniqKey="Schuurman R">R Schuurman</name></author><author><name sortKey="Hoepelman, Aim" uniqKey="Hoepelman A">AIM Hoepelman</name></author><author><name sortKey="Wensing, Amj" uniqKey="Wensing A">AMJ Wensing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whitcomb, Jm" uniqKey="Whitcomb J">JM Whitcomb</name></author><author><name sortKey="Parkin, Nt" uniqKey="Parkin N">NT Parkin</name></author><author><name sortKey="Chappey, C" uniqKey="Chappey C">C Chappey</name></author><author><name sortKey="Hellmann, Ns" uniqKey="Hellmann N">NS Hellmann</name></author><author><name sortKey="Petropoulos, Cj" uniqKey="Petropoulos C">CJ Petropoulos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simen, Bb" uniqKey="Simen B">BB Simen</name></author><author><name sortKey="Simons, Jf" uniqKey="Simons J">JF Simons</name></author><author><name sortKey="Hullsiek, Kh" uniqKey="Hullsiek K">KH Hullsiek</name></author><author><name sortKey="Novak, Rm" uniqKey="Novak R">RM Novak</name></author><author><name sortKey="Macarthur, Rd" uniqKey="Macarthur R">RD MacArthur</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lataillade, M" uniqKey="Lataillade M">M Lataillade</name></author><author><name sortKey="Chiarella, J" uniqKey="Chiarella J">J Chiarella</name></author><author><name sortKey="Yang, R" uniqKey="Yang R">R Yang</name></author><author><name sortKey="Schnittman, S" uniqKey="Schnittman S">S Schnittman</name></author><author><name sortKey="Wirtz, V" uniqKey="Wirtz V">V Wirtz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, C" uniqKey="Wang C">C Wang</name></author><author><name sortKey="Mitsuya, Y" uniqKey="Mitsuya Y">Y Mitsuya</name></author><author><name sortKey="Gharizadeh, B" uniqKey="Gharizadeh B">B Gharizadeh</name></author><author><name sortKey="Ronaghi, M" uniqKey="Ronaghi M">M Ronaghi</name></author><author><name sortKey="Shafer, Rw" uniqKey="Shafer R">RW Shafer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pacold, M" uniqKey="Pacold M">M Pacold</name></author><author><name sortKey="Smith, D" uniqKey="Smith D">D Smith</name></author><author><name sortKey="Little, S" uniqKey="Little S">S Little</name></author><author><name sortKey="Cheng, Pm" uniqKey="Cheng P">PM Cheng</name></author><author><name sortKey="Jordan, P" uniqKey="Jordan P">P Jordan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Redd, Ad" uniqKey="Redd A">AD Redd</name></author><author><name sortKey="Collinson Streng, A" uniqKey="Collinson Streng A">A Collinson-Streng</name></author><author><name sortKey="Martens, C" uniqKey="Martens C">C Martens</name></author><author><name sortKey="Ricklefs, S" uniqKey="Ricklefs S">S Ricklefs</name></author><author><name sortKey="Mullis, Ce" uniqKey="Mullis C">CE Mullis</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23977189</article-id><article-id pub-id-type="pmc">3747072</article-id><article-id pub-id-type="publisher-id">PONE-D-13-14356</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0071972</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Transmission and Infection</subject><subj-group><subject>Viral Load</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Biostatistics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Molecular Epidemiology</subject></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV diagnosis and management</subject><subject>HIV epidemiology</subject><subject>Retrovirology and HIV immunopathogenesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Health Screening</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana</article-title><alt-title alt-title-type="running-head">HIV-1 Drug-Resistance Surveillance in Ghana</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Nii-Trebi</surname><given-names>Nicholas I.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ibe</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Barnor</surname><given-names>Jacob S.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ishikawa</surname><given-names>Koichi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brandful</surname><given-names>James A. M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ofori</surname><given-names>Sampson B.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamaoka</surname><given-names>Shoji</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ampofo</surname><given-names>William K.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sugiura</surname><given-names>Wataru</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Ghana, Accra, Ghana</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Infection and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana</addr-line></aff><aff id="aff4"><label>4</label><addr-line>AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Medicine, Koforidua Regional Hospital, Koforidua, Ghana</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Department of AIDS Research, Nagoya University Graduate School of Medicine, Nagoya, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Barbour</surname><given-names>Jason D.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>University of Hawaii Manoa, United States of America</addr-line></aff><author-notes><corresp id="cor1">* E-mail: <email>wsugiura@nnh.hosp.go.jp</email></corresp><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: NIN SI JSB KI JAMB SBO SY WKA WS. Performed the experiments: NIN SI JSB KI JAMB. Wrote the paper: NIN SI WS. Organized the study team: KI SY WKA WS. Enrolled patients into the study: SBO. Prepared a clinical database: NIN JSB KI SBO. Revised the manuscript critically JSB KI JAMB SBO SY WKA.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>8</month><year>2013</year></pub-date><volume>8</volume><issue>8</issue><elocation-id>e71972</elocation-id><history><date date-type="received"><day>7</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2013</year></date></history><permissions><copyright-year>2013</copyright-year><copyright-holder>Nii-Trebi et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly diagnosed individuals in Ghana.</p></sec><sec><title>Methods</title><p>Samples were collected from 101 HIV-1-infected patients (32 ART-experienced cases with virological failure and 69 newly diagnosed ART-naïve cases, including 11 children), in Koforidua, Eastern region of Ghana, from February 2009 to January 2010. The <italic>pol</italic> gene sequences were analyzed by in-house HIV-1 drug-resistance testing.</p></sec><sec><title>Results</title><p>The most prevalent HIV-1 subtype was CRF02_AG (66.3%, 67/101) followed by unique recombinant forms (25.7%, 26/101). Among 31 ART-experienced adults, 22 (71.0%) possessed at least one drug-resistance mutation, and 14 (45.2%) had two-class-resistance to nucleoside and non-nucleoside reverse-transcriptase inhibitors used in their first ART regimen. Importantly, the number of accumulated mutations clearly correlated with the duration of ART. The most prevalent mutation was lamivudine-resistance M184V (<italic>n</italic> = 12, 38.7%) followed by efavirenz/nevirapine-resistance K103N (<italic>n</italic> = 9, 29.0%), and zidovudine/stavudine-resistance T215Y/F (<italic>n</italic> = 6, 19.4%). Within the viral protease, the major nelfinavir-resistance mutation L90M was found in one case. No transmitted HIV-1 drug-resistance mutation was found in 59 ART-naïve adults, but K103N and G190S mutations were observed in one ART-naïve child.</p></sec><sec><title>Conclusions</title><p>Despite expanding accessibility to ART in Eastern Ghana, the prevalence of transmitted HIV-1 drug resistance presently appears to be low. As ART provision with limited options is scaled up nationwide in Ghana, careful monitoring of transmitted HIV-1 drug resistance is necessary.</p></sec></abstract><funding-group><funding-statement>This study was supported by a grant of the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology of Japan to the University of Ghana; the Tokyo Medical and Dental University; a Grant-in-Aid for AIDS Research from the Ministry of Health, Labour and Welfare of Japan (H22-AIDS-004); and a grant from the HIV Research Trust, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The number of people worldwide living with HIV/AIDS in 2010, according to the latest report from the United Nations Programme on HIV/AIDS, was estimated to be 34.0 million <xref ref-type="bibr" rid="pone.0071972-UNAIDS1">[1]</xref>. Although the highest prevalence of HIV/AIDS remains in sub-Saharan Africa, current massive and rapid scaling up of antiretroviral therapy (ART) has resulted in the decline of the epidemic in this region <xref ref-type="bibr" rid="pone.0071972-UNAIDS1">[1]</xref>. Indeed, HIV prevalence in Ghana gradually declined from a peak of 3.6% in 2003 to 2.1% in 2011 due to the National AIDS Control Programme implementing a strategy for achieving universal access to ART. The program has been continuously expanding since 2003, and the coverage of ART in 2011 was estimated to be 26.6% (59,007/221,884) and 63.6% (8,057/12,661) for total HIV-infected individuals and for HIV-positive pregnant women, respectively <xref ref-type="bibr" rid="pone.0071972-Ghana1">[2]</xref>.</p><p>The first-line regimen of ART recommended in Ghana is the combination of two nucleoside reverse-transcriptase inhibitors (NRTIs) and a non-nucleoside reverse-transcriptase inhibitor (NNRTI) <xref ref-type="bibr" rid="pone.0071972-National1">[3]</xref>. Specifically, the two NRTIs selected are lamivudine (3TC) and either zidovudine (AZT) or stavudine (d4T), then either nevirapine (NVP) or efavirenz (EFV) as the NNRTI <xref ref-type="bibr" rid="pone.0071972-National1">[3]</xref>. For the second-line regimen in Ghana, two protease inhibitors (PIs) are available, nelfinavir (NFV) or lopinavir/ritonavir (LPV/r), either of which is recommended to use with two NRTIs, abacavir (ABC) and either tenofovir (TDF) or didanosine (ddI) <xref ref-type="bibr" rid="pone.0071972-National1">[3]</xref>.</p><p>Drug-resistant HIV variants selected during ART have the potential to be transmitted to others. Indeed, drug-resistant HIV has been widely described in ART-naïve individuals. For example, a recent systematic review revealed that the overall prevalence of drug-resistant HIV-1 transmission reached 12.9% in North America, 10.9% in Europe, 6.3% in Latin America, 4.7% in Africa, and 4.2% in Asia <xref ref-type="bibr" rid="pone.0071972-Frentz1">[4]</xref>. Thus, the higher prevalence of drug-resistant HIV-1 transmission has been reported in higher ART coverage areas, mostly in developed countries. It is important to note that, along with ART scale-up, the prevalence of transmitted HIV-1 drug-resistance increased from 2.8% before 2001 to 5.3% after 2003 in African countries <xref ref-type="bibr" rid="pone.0071972-Frentz1">[4]</xref>. As the transmission of drug-resistant HIV may seriously affect the efficacy of first-line ART, surveillance to monitor the prevalence of transmitted HIV drug-resistance has become an important issue in African countries. The prevalence of transmitted HIV-1 drug resistance in Ghana was reported in two studies. One was conducted in 2003 in the Greater-Accra Region of Ghana <xref ref-type="bibr" rid="pone.0071972-Sagoe1">[5]</xref>, and the other one was conducted between 2002 and 2004 in Accra and two sites of the Eastern region, Agomanya and Atua <xref ref-type="bibr" rid="pone.0071972-Delgado1">[6]</xref>. Both studies reported no case of drug-resistant HIV-1 transmission <xref ref-type="bibr" rid="pone.0071972-Sagoe1">[5]</xref>, <xref ref-type="bibr" rid="pone.0071972-Delgado1">[6]</xref>. As at December 2009, the national response had established programs for the provision of ART in hospitals and health centers in several districts in the ten regions of Ghana <xref ref-type="bibr" rid="pone.0071972-Ampofo1">[7]</xref>. However, since ART was expanded in Ghana, the situation of transmitted HIV-1 drug-resistance has not been reported.</p><p>To clarify the prevalence, pattern, and spectrum of HIV-1 drug resistance in the era of scaled up ART in Ghana, particularly in ART-experienced patients and transmission to new individuals, we surveyed HIV-1 drug resistance among ART-experienced and -naïve patients enrolled between 2009 and 2010 in Koforidua, the capital of the Eastern region, Ghana. Concomitantly, we analyzed HIV-1 subtypes in detail to further understand the epidemiology of HIV-1 infections in Ghana.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Patients</title><p>HIV-infected patients who visited the Koforidua Regional Hospital (KRH) from February 2009 to January 2010 were enrolled in the study. KRH is the main HIV/AIDS clinic in the capital of the Eastern region of Ghana. This hospital is responsible for HIV prevention and intervention programs in the area and provides free ART with care and support to HIV-infected patients. The Institutional Review Board of the Noguchi Memorial Institute for Medical Research granted ethical approval for this study. All patients or their caregivers gave written consent to participate in the study.</p></sec><sec id="s2b"><title>CD4<sup>+</sup> T-cell Count and Plasma HIV-1 Viral Load Monitoring</title><p>For an indication of immune status, CD4<sup>+</sup> T-cells were measured using a FACSCount flow cytometer (Becton Dickinson, San Jose, California, USA). Plasma HIV-1 viral loads (pVLs) were quantified using an in-house real-time reverse-transcription and polymerase chain reaction (RT-PCR) assay as previously reported <xref ref-type="bibr" rid="pone.0071972-Barnor1">[8]</xref>. ART-experienced patients with pVL>150 copies/mL were considered as virological failures.</p></sec><sec id="s2c"><title>HIV-1 Drug-resistance Genotyping</title><p>HIV-1 drug-resistance genotyping was performed as previously reported with some modifications <xref ref-type="bibr" rid="pone.0071972-ChibaMizutani1">[9]</xref>. In brief, viral RNA was extracted from 200 µL of plasma samples using QIAamp viral RNA mini kit (Qiagen, Hilden, Germany). RT-PCR was performed with QIAGEN one-step RT-PCR kit (Qiagen), and nested PCR was subsequently performed using AmpliTaq DNA polymerase (Applied Biosystems, Foster City, USA). Specific primers known as DRPRO5, DRPRO2L, DRPRO1M, and DRPRO6 were used for the protease (PR) region (424 bp, positions 2,168 to 2,591 in the reference HXB2 sequence), and DRRT1L, DRRT4L, DRRT7L, and DRRT6L primers for the reverse transcriptase (RT) region (838 bp, positions 2,510 to 3,347) <xref ref-type="bibr" rid="pone.0071972-ChibaMizutani1">[9]</xref>. Details of the primers used in the study are shown in <xref ref-type="table" rid="pone-0071972-t001">Table 1</xref>. Nucleotide sequencing was performed using ABI 3730 auto-sequencer followed by editing with SeqScape software v2.5 (Applied Biosystems). HIV-1 drug-resistance mutations were detected according to the latest definition of the International AIDS Society-USA panel <xref ref-type="bibr" rid="pone.0071972-Johnson1">[10]</xref>. In addition, transmitted HIV-1 drug-resistance mutations were defined using the mutation list proposed by Bennett et al. <xref ref-type="bibr" rid="pone.0071972-Bennett1">[11]</xref>.</p><table-wrap id="pone-0071972-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.t001</object-id><label>Table 1</label><caption><title>List of primers used in HIV-1 genotypic drug-resistance testing.</title></caption><alternatives><graphic id="pone-0071972-t001-1" xlink:href="pone.0071972.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Target region</td><td colspan="2" align="left" rowspan="1">Amplicon</td><td colspan="4" align="left" rowspan="1">Primers</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Size (bp)</td><td align="left" rowspan="1" colspan="1">Position<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">Reaction</td><td align="left" rowspan="1" colspan="1">Direction</td><td align="left" rowspan="1" colspan="1">Name</td><td align="left" rowspan="1" colspan="1">Nucleotide sequence (5′ to 3′)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">424</td><td align="left" rowspan="1" colspan="1">2,168 to 2,591</td><td align="left" rowspan="1" colspan="1">RT-PCR</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">DRPRO5</td><td align="left" rowspan="1" colspan="1">AGA CAG GYT <named-content content-type="gene">AAT TTT TTA GGG A</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">DRPRO2L</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TAT GGA TTT TCA GGC CCA ATT TTT GA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Nested PCR</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">DRPRO1M</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGA GCC AAC AGC CCC ACC AG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">DRPRO6</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACT TTT GGG CCA TCC ATT CC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">Reverse transcriptase</td><td align="left" rowspan="1" colspan="1">838</td><td align="left" rowspan="1" colspan="1">2,510 to 3,347</td><td align="left" rowspan="1" colspan="1">RT-PCR</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">DRRT1L</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATG ATA GGG GGA ATT GGA GGT TT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">DRRT4L</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TAC TTC TGT TAG TGC TTT GGT TCC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Nested PCR</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">DRRT7L</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAC CTA CAC CTG TCA ACA TAA TTG G</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">DRRT6L</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TAA TCC CTG CAT AAA TCT GAC TTG C</named-content></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label></label><p>bp, base pairs; PCR, polymerase chain reaction; and RT-PCR, reverse transcription and polymerase chain reaction.</p></fn><fn id="nt102"><label>a</label><p>Amplicon positions in the reference HIV-1 HXB2 sequence are represented.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d"><title>HIV-1 Subtyping</title><p>HIV-1 subtyping was performed using the <italic>pol</italic> gene sequences (1,095 bp, positions 2253 to 3347). Phylogenetic tree was constructed with the references of subtypes A-D, F-H, J, K, and all circulating recombinant forms (CRFs) 01 to 51, except 30, 41, and 50, obtained from the HIV Sequence Database at the Los Alamos National Laboratory. In addition, HIV-1 sub-subtype A3 (DDI579, DDJ360, and DDJ369) and A4 (97CD_KCC2, 97CD_KTB13, and 02CD_KTB035) isolates were added to the phylogenetic tree analysis, as these sub-subtypes have been reported as circulating in several African countries <xref ref-type="bibr" rid="pone.0071972-Meloni1">[12]</xref>, <xref ref-type="bibr" rid="pone.0071972-Vidal1">[13]</xref>. Multiple sequences were aligned using the MUSCLE program, and genetic distances were calculated based on the maximum composite likelihood model using MEGA software v5.05 <xref ref-type="bibr" rid="pone.0071972-Tamura1">[14]</xref>. Phylogenetic trees were constructed using the neighbor-joining method with 1,000 bootstrap replicates. In similarity plotting and boot-scanning analyses, nine HIV-1 subtypes, A-D, F-H, J, and K, and three CRFs, CRF02_AG, CRF06_cpx, and CRF09_cpx, were used as references. Similarity plotting and boot-scanning were performed using SimPlot software v3.5.1 with window and step sizes of 250 and 20 nucleotides, respectively <xref ref-type="bibr" rid="pone.0071972-Lole1">[15]</xref>. One HIV-1 isolate identified with an unknown mosaic pattern both in similarity plotting and boot-scanning analyses was considered as a unique recombinant form (URF).</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>The Fisher’s exact test and the Mann-Whitney U-test were used in SYSTAT software v10.2 (SYSTAT Software, Chicago, USA) for analysis of statistical significance between categorical variables and quantitative valuables, respectively. All tests were two-sided and the level of significance was set at <italic>P</italic><0.05.</p></sec><sec id="s2f"><title>Accession Numbers</title><p>Nucleotide sequences have been registered as #AB751399 to AB751499 in the DNA databank of Japan.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>CRF02_AG is the Predominant HIV-1 Strain in Koforidua, Ghana</title><p>During the study period, 101 HIV-1-infected patients were enrolled in this study. As shown in <xref ref-type="table" rid="pone-0071972-t002">Table 2</xref>, 90 cases were adults (≧15 years old), including 59 newly diagnosed ART-naïve cases and 31 ART-experienced cases. The remaining 11 cases were children (<15 years old), among which were 10 newly diagnosed ART-naïve cases while one child was ART-experienced (<xref ref-type="table" rid="pone-0071972-t003">Table 3</xref>). To understand the molecular epidemiology of HIV-1 infections in Ghana, we analyzed the <italic>pol</italic> gene sequences in detail through the construction of phylogenetic trees, similarity plotting, and boot-scanning analyses. Among the 101 cases, 75 (74.3%) were identified as HIV-1 subtypes and CRFs (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1A</xref>); 67 were CRF02_AG (66.3%), 4 were sub-subtype A3 (4.0%), 2 were CRF06_cpx (2.0%), and 2 were CRF09_cpx (2.0%). Thus, our analyses clearly showed the predominance of HIV-1 CRF02_AG in Koforidua.</p><fig id="pone-0071972-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.g001</object-id><label>Figure 1</label><caption><title>Molecular epidemiology of HIV-1 infections in Koforidua, Ghana.</title><p>HIV-1 subtypes of 101 isolates were determined through the construction of phylogenetic trees, similarity plotting, and boot-scanning analyses. (A) Phylogenetic tree containing our 75 isolates classified into known subtypes and CRFs. (B) Phylogenetic tree containing our 26 URF isolates identified with unknown mosaic patterns of the <italic>pol</italic> gene. Two clusters of URF isolates are represented by #1 and #2. (C) Summary on the chimeric patterns of 26 URF isolates. The trees were constructed by the neighbor-joining method. Bootstrap values were calculated from 1,000 analyses, and values greater than 70% are shown at tree nodes. Our isolates are represented by colored circles, and subtype reference isolates are represented by their subtype and name. Scale bar represents nucleotide substitutions per site. HIV-1 group O isolate, ANT70, was used as the outgroup. CRF, circulating recombinant form; PR, protease; RT, reverse transcriptase; and URF, unique recombinant form.</p></caption><graphic xlink:href="pone.0071972.g001"></graphic></fig><table-wrap id="pone-0071972-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.t002</object-id><label>Table 2</label><caption><title>Demographic and clinical characteristics of ART-experienced and -naïve HIV-1-infected patients ≧15 years old (<italic>n</italic> = 90).</title></caption><alternatives><graphic id="pone-0071972-t002-2" xlink:href="pone.0071972.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">ART-experienced, <italic>n</italic> = 31</td><td align="left" rowspan="1" colspan="1">ART-naïve, <italic>n</italic> = 59</td><td align="left" rowspan="1" colspan="1"><italic>P</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">38 (35–43)</td><td align="left" rowspan="1" colspan="1">42 (32–49)</td><td align="left" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (%)</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">18 (58.1)</td><td align="left" rowspan="1" colspan="1">38 (64.4)</td><td align="left" rowspan="1" colspan="1">0.649</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">13 (41.9)</td><td align="left" rowspan="1" colspan="1">21 (35.6)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Risk factor for HIV infection (%)</td><td align="left" rowspan="1" colspan="1">Heterosexual contact</td><td align="left" rowspan="1" colspan="1">31 (100.0)</td><td align="left" rowspan="1" colspan="1">57 (96.6)</td><td align="left" rowspan="1" colspan="1">0.543</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Transfusion</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">HIV serology (%)<xref ref-type="table-fn" rid="nt104">a</xref></td><td align="left" rowspan="1" colspan="1">HIV-1 positive</td><td align="left" rowspan="1" colspan="1">29 (93.5)</td><td align="left" rowspan="1" colspan="1">59 (100.0)</td><td align="left" rowspan="1" colspan="1">0.116</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">HIV-1 and -2 positive</td><td align="left" rowspan="1" colspan="1">2 (6.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T-cell count, cells/µl</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">230 (87–376)</td><td align="left" rowspan="1" colspan="1">237 (86–426)</td><td align="left" rowspan="1" colspan="1">0.750</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-1 viral load, log<sub>10</sub> copies/ml</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">3.7 (3.3–4.1)</td><td align="left" rowspan="1" colspan="1">4.4 (3.7–5.0)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-1 genotype (%)</td><td align="left" rowspan="1" colspan="1">CFR02_AG</td><td align="left" rowspan="1" colspan="1">18 (58.1)</td><td align="left" rowspan="1" colspan="1">42 (71.2)</td><td align="left" rowspan="1" colspan="1">0.638</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">A3</td><td align="left" rowspan="1" colspan="1">2 (6.5)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">CRF06_cpx</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">CRF09_cpx</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">URF</td><td align="left" rowspan="1" colspan="1">9 (29.0)</td><td align="left" rowspan="1" colspan="1">13 (22.0)</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td colspan="2" align="left" rowspan="1">ART regimen (%)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1">First line</td><td align="left" rowspan="1" colspan="1">d4T+3TC+EFV</td><td align="left" rowspan="1" colspan="1">10 (32.3)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">AZT+3TC+NVP</td><td align="left" rowspan="1" colspan="1">10 (32.3)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">AZT+3TC+EFV</td><td align="left" rowspan="1" colspan="1">7 (22.6)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">d4T+3TC+NVP</td><td align="left" rowspan="1" colspan="1">3 (9.7)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Second line</td><td align="left" rowspan="1" colspan="1">AZT+3TC+NFV</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ART, months</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">16.1 (6.8–30.3)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1">Adherence (%)<xref ref-type="table-fn" rid="nt105">b</xref></td><td align="left" rowspan="1" colspan="1">Good</td><td align="left" rowspan="1" colspan="1">17 (54.8)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Satisfactory</td><td align="left" rowspan="1" colspan="1">8 (25.8)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Poor</td><td align="left" rowspan="1" colspan="1">6 (19.4)</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label></label><p>ART, antiretroviral therapy; AZT, zidovudine; CRF, circulating recombinant form; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NFV, nelfinavir; NVP, nevirapine; 3TC, lamivudine; and URF, unique recombinant form.</p></fn><fn id="nt104"><label>a</label><p>HIV serology was determined using New LAV Blot I and II (Bio-Rad Laboratories, Marnes-la-Coquette, France).</p></fn><fn id="nt105"><label>b</label><p>Good, 100% pills taken; Satisfactory, ≧95%, but <100% pills taken; Poor, <95% pills taken.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0071972-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.t003</object-id><label>Table 3</label><caption><title>Demographic and clinical characteristics of HIV-1-infected patients <15 years old (<italic>n</italic> = 11)<xref ref-type="table-fn" rid="nt107"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone-0071972-t003-3" xlink:href="pone.0071972.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">Value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">5.0 (1.5–8.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (%)</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">6 (54.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">5 (45.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T-cell count, cells/µl</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">747 (474–1152)</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-1 viral load, log<sub>10</sub>copies/ml</td><td align="left" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">4.3 (3.4–4.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-1 genotype (%)</td><td align="left" rowspan="1" colspan="1">CRF02_AG</td><td align="left" rowspan="1" colspan="1">7 (63.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">URF</td><td align="left" rowspan="1" colspan="1">4 (36.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">ART (%)</td><td align="left" rowspan="1" colspan="1">Naïve</td><td align="left" rowspan="1" colspan="1">10 (90.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">d4T+3TC+EFV<xref ref-type="table-fn" rid="nt108">b</xref></td><td align="left" rowspan="1" colspan="1">1 (9.1)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label></label><p>ART, antiretroviral therapy; CRF, circulating recombinant form; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; 3TC, lamivudine; and URF, unique recombinant form.</p></fn><fn id="nt107"><label>a</label><p>All were HIV-1 seropositive alone, and their risk factor for infection was mother-to-child transmission.</p></fn><fn id="nt108"><label>b</label><p>Only one case had been on treatment for 9.6 months.</p></fn></table-wrap-foot></table-wrap><p>Interestingly, the remaining 26 cases (25.7%) were identified as HIV-1 URFs (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1B</xref>). The most prevalent chimeric pattern was CRF02/A3 (<italic>n</italic> = 11, 10.9%), followed by CRF02/CRF06 (<italic>n</italic> = 5, 5.0%), CRF02/G (<italic>n</italic> = 2, 2.0%), CRF02/CRF09 (<italic>n</italic> = 2, 2.0%), and 6 other patterns (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1C</xref>). Of note, two interesting clusters were found in the phylogenetic tree of URF isolates (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1B</xref>). Cluster #1 with three isolates, 09GH.120495, 09GH.1765, and 09GH.KF47, shared the same mosaic <italic>pol</italic> gene comprising a large PR and RT fragment of CRF02 and a short RT fragment of A3 (cluster #1, <xref ref-type="fig" rid="pone-0071972-g001">Fig. 1B</xref>). Cluster #2 with the other three isolates, 09GH.107421, 09GH.60390, and 09GH.KF43, shared the same mosaic <italic>pol</italic> gene comprising the PR fragment of A3 and two RT fragments of CRF02 and A3 (cluster #2, <xref ref-type="fig" rid="pone-0071972-g001">Fig. 1B</xref>). Our data suggest that the two URF clusters are candidates for a new CRF spreading in this area of Ghana.</p></sec><sec id="s3b"><title>HIV-1 Drug-resistance Mutations are Highly Frequent among ART-experienced Cases with Virological Failure Status</title><p>Demographic and clinical characteristics of 31 ART-experienced adult cases are shown in <xref ref-type="table" rid="pone-0071972-t002">Table 2</xref>. All patients except one (96.8%, 30/31) were treated with the first-line ART regimen of 2 NRTIs+NNRTI, and the remaining one (3.2%) with the second-line ART regimen of 2 NRTIs+PI. Their median duration of ART was 16.1 months (IQR, 6.8–30.3 months), and most cases maintained their adherence at a “good” or “satisfactory” level (80.6%, 25/31).</p><p>Among these ART-experienced adult cases, 22 cases (71.0%) possessed one or more HIV-1 drug-resistance mutations (<xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>). The most prevalent drug-resistance pattern was 2-class resistance to NRTI and NNRTI (<italic>n</italic> = 13, 41.9%), followed by 1-class resistance to NNRTI (<italic>n</italic> = 8, 25.8%). Of note, 3-class resistance was identified in one case (3.2%) treated with the second-line regimen AZT+3TC+NFV. This case possessed HIV-1 RT mutations M41L, V90I, A98G, M184V and T215Y, and the major NFV-resistance mutation L90M in PR. As shown in <xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>, the most prevalent drug-resistance mutation among the 31 cases was M184V (<italic>n</italic> = 12, 38.7%), followed by K103N (<italic>n</italic> = 9, 29.0%), and T215Y/F (<italic>n</italic> = 6, 19.4%). No drug-resistance mutation was detected in the remaining 9 cases (29.0%, <xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>), suggesting that acquisitions of drug resistance was not the primary cause of their virological failure. The cases with and without resistance did not differ significantly in their demographic characteristics.</p><table-wrap id="pone-0071972-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.t004</object-id><label>Table 4</label><caption><title>Frequency of HIV-1 drug-resistance mutations in ART-experienced and -naïve adult patients (≧15 years old) (<italic>n</italic> = 90)<xref ref-type="table-fn" rid="nt110"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone-0071972-t004-4" xlink:href="pone.0071972.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Mutation</td><td align="left" rowspan="1" colspan="1">ART-experienced, <italic>n</italic> = 31 (%)</td><td align="left" rowspan="1" colspan="1">ART-naïve, <italic>n</italic> = 59 (%)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any</td><td align="left" rowspan="1" colspan="1">22 (71.0)</td><td align="left" rowspan="1" colspan="1">6 (10.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">NNRTI resistance</td><td align="left" rowspan="1" colspan="1">8 (25.8)</td><td align="left" rowspan="1" colspan="1">6 (10.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">NRTI and NNRTI resistance</td><td align="left" rowspan="1" colspan="1">13 (41.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">NRTI, NNRTI, and PI resistance</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Transmitted drug resistance</td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">9 (29.0)</td><td align="left" rowspan="1" colspan="1">53 (89.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">NRTI-resistance mutation</td><td align="left" rowspan="1" colspan="1">14 (45.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> A62V</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> M184V</td><td align="left" rowspan="1" colspan="1">12 (38.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">TAMs</td><td align="left" rowspan="1" colspan="1">8 (25.8)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> M41L</td><td align="left" rowspan="1" colspan="1">4 (12.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> D67N</td><td align="left" rowspan="1" colspan="1">3 (9.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> K70R</td><td align="left" rowspan="1" colspan="1">4 (12.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> L210W</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> T215Y</td><td align="left" rowspan="1" colspan="1">5 (16.1)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> T215F</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> K219Q</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> K219E</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">NNTRI-resistance mutation</td><td align="left" rowspan="1" colspan="1">22 (71.0)</td><td align="left" rowspan="1" colspan="1">6 (10.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"> V90I</td><td align="left" rowspan="1" colspan="1">4 (12.9)</td><td align="left" rowspan="1" colspan="1">4 (6.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"> A98G</td><td align="left" rowspan="1" colspan="1">5 (16.1)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> K103N</td><td align="left" rowspan="1" colspan="1">9 (29.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> V106I</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"> V106A</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> V108I</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> E138A</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Y181C</td><td align="left" rowspan="1" colspan="1">3 (9.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Y188L</td><td align="left" rowspan="1" colspan="1">2 (6.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> G190A</td><td align="left" rowspan="1" colspan="1">2 (6.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> P225H</td><td align="left" rowspan="1" colspan="1">3 (9.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> M230L</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">PI-resistance major mutation</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"> L90M</td><td align="left" rowspan="1" colspan="1">1 (3.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label></label><p>ART, antiretroviral therapy; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; and TAMs, thymidine analog-associated mutations.</p></fn><fn id="nt110"><label>a</label><p>HIV-1 drug-resistance mutations were detected according to the latest definition of the International AIDS Society-USA panel <xref ref-type="bibr" rid="pone.0071972-Johnson1">[10]</xref>. For ART-naïve patients, transmitted drug resistance was defined according to the latest definition of the WHO drug-resistance surveillance <xref ref-type="bibr" rid="pone.0071972-Bennett1">[11]</xref>.</p></fn></table-wrap-foot></table-wrap><p>Furthermore, we analyzed the chronological order of acquiring drug resistance to 3TC, NVP, EFV, AZT, and d4T. As shown in <xref ref-type="fig" rid="pone-0071972-g002">Fig. 2A</xref>, no mutation was found in any patients, even with viremia, who had received ART for ≦6.0 months (0%, 0/6). However, M184V mutation was detected in 37.5% (3/8) of patients with 6.1–12.0 months of ART, and the prevalence increased to 80.0% (4/5) at ≧36.1 months of ART (red bars in <xref ref-type="fig" rid="pone-0071972-g002">Fig. 2A and 2B</xref>). In the case of NVP and EFV resistance, K103N, V106A, V108I, Y181C/L, G190A, P225H, and M230L mutations were detected in more than half of patients after 6.0 months of ART (blue bars in <xref ref-type="fig" rid="pone-0071972-g002">Fig. 2A and 2B</xref>). Importantly, the prevalence and accumulation of thymidine analog-associated mutations (TAMs) appeared to be higher with longer duration of ART; 16.7% (1/6) at 12.1–24.0 months to 100% (5/5) at ≧36.1 months of ART (green bars in <xref ref-type="fig" rid="pone-0071972-g002">Fig. 2A and 2B</xref>).</p><fig id="pone-0071972-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.g002</object-id><label>Figure 2</label><caption><title>Prevalence of 3TC-, NVP-, EFV-, AZT-, and d4T-resistance mutations by duration of ART in 31 HIV-1-infected patients ≧15 years old.</title><p>(A) Bar graph and (B) details of 17 patients identified with 3TC-, NVP-, EFV-, AZT-, and d4T-resistance mutations. HIV-1 drug-resistance mutations were detected according to the latest definition of the International AIDS Society-USA panel <xref ref-type="bibr" rid="pone.0071972-Johnson1">[10]</xref>. Amino acid mutations responsible for drug resistance are shown in bold and color coded with bar graph in A. *Major NFV-resistance mutation L90M was found in the protease in the case of KF307. ART, antiretroviral therapy; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; NFV, nelfinavir; NVP, nevirapine; and 3TC, lamivudine.</p></caption><graphic xlink:href="pone.0071972.g002"></graphic></fig></sec><sec id="s3c"><title>Low HIV-1 Drug-resistance Transmission in ART-naïve Cases</title><p>The general demographics of the 59 adult ART-naïve cases were similar to those of the treated cases, however pVL was significantly higher in the naïve cases (<italic>P</italic> = 0.006) (<xref ref-type="table" rid="pone-0071972-t002">Table 2</xref>). Among the ART-naïve cases, no transmitted HIV-1 drug-resistance mutation was found (<xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>). However, polymorphisms at NNRTI-resistance mutation loci, V90I, E138A, and V106I, were found in 6 cases (10.2% in <xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>). Our data indicated that drug-resistant HIV-1 transmission events are still low in Koforidua, Ghana.</p><p>Eleven children infected with HIV-1 through mother-to-child transmission were also analyzed in our study (<xref ref-type="table" rid="pone-0071972-t003">Table 3</xref>). Their median age was 5.0 years (IQR, 1.5–8.0 years), and 10 of these cases were ART naïve. The remaining case had been treated with d4T+3TC+EFV for 9.6 months but had become viremic. In this case, both 3TC-resistance (M184V) and EFV-resistance (V108I and G190S) mutations were detected (<xref ref-type="table" rid="pone-0071972-t005">Table 5</xref>). Importantly, among the 10 ART-naïve children, a 1.5-year-old case had K103N and G190S NNRTI-resistance mutations (<xref ref-type="table" rid="pone-0071972-t005">Table 5</xref>), suggesting the importance of HIV-1 drug-resistance testing in infants.</p><table-wrap id="pone-0071972-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0071972.t005</object-id><label>Table 5</label><caption><title>HIV-1 drug-resistance mutations in patients <15 years old (<italic>n</italic> = 11)<xref ref-type="table-fn" rid="nt112"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone-0071972-t005-5" xlink:href="pone.0071972.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">ART</td><td align="left" rowspan="1" colspan="1"><italic>n</italic></td><td colspan="2" align="left" rowspan="1">Amino acid mutations associated with</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">NNRTI resistance</td><td align="left" rowspan="1" colspan="1">NRTI resistance</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Naïve</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">−</td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">V90I, V106I</td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">V90I</td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"><bold><underline>K103N</underline></bold>, <bold><underline>G190S</underline></bold></td><td align="left" rowspan="1" colspan="1">−</td></tr><tr><td align="left" rowspan="1" colspan="1">d4T+3TC+EFV</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">K101E, V106I, V108I, G190S</td><td align="left" rowspan="1" colspan="1">M184V</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt111"><label></label><p>ART, antiretroviral therapy; d4T, stavudine; EFV, efavirenz; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; and 3TC, lamivudine.</p></fn><fn id="nt112"><label>a</label><p>HIV-1 drug-resistance mutations were detected according to the latest definition of the International AIDS Society-USA panel <xref ref-type="bibr" rid="pone.0071972-Johnson1">[10]</xref>. For ART-naïve patients, transmitted drug-resistance (shown in bold and underlined) was detected according to the latest definition of the WHO drug-resistance surveillance <xref ref-type="bibr" rid="pone.0071972-Bennett1">[11]</xref>.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>Our results present a profile of the circulating subtypes and prevalence of drug resistance for HIV-1 infections in Koforidua, Ghana. The data clearly demonstrate the predominance of HIV-1 CRF02_AG (66.3%, <italic>n</italic> = 67) in the region (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1A</xref>). Our results, combined with three previous reports on the domination of CRF02_AG in Ghana between 1994 and 2004 <xref ref-type="bibr" rid="pone.0071972-Sagoe1">[5]</xref>, <xref ref-type="bibr" rid="pone.0071972-Delgado1">[6]</xref>, <xref ref-type="bibr" rid="pone.0071972-Fischetti1">[16]</xref>, indicate that CRF02_AG has stabilized and maintained its predominance in the region for nearly 12 years. However, our study identified 26 isolates (25.7%) as URFs (<xref ref-type="fig" rid="pone-0071972-g001">Fig. 1B</xref>), indicating that active viral recombinations are ongoing in Ghana. Interestingly, a similar prevalence (25.1%) of HIV-1 URFs was reported from other cities in Ghana, Accra, Agomanya, and Atua <xref ref-type="bibr" rid="pone.0071972-Delgado1">[6]</xref>. Taken together, these data thus highlight the importance of HIV-1 URFs in understanding the dynamics of the HIV-1 epidemic in Ghana.</p><p>Regarding the situation of HIV-1 drug resistance in Ghana, most of the 31 patients on treatment with virological failure (<italic>n</italic> = 22, 71.0%) had HIV-1 drug-resistance mutations, suggesting that drug-resistant HIV-1 is the major risk factor for virological failure. Furthermore, nearly half of the cases (45.2%, 14/31) had both NRTI- and NNRTI-resistance mutations (<xref ref-type="table" rid="pone-0071972-t004">Table 4</xref>), a pattern that is consistent with that observed in a recent systematic review on treatment-failure cases in sub-Saharan Africa <xref ref-type="bibr" rid="pone.0071972-Barth1">[17]</xref>, where M184V/I, K103N, and T215Y/F mutations predominate.</p><p>Regarding the timing of drug-resistance acquisition, our data demonstrated that 3TC-, NVP-, and EFV-resistance mutations were selected earlier (6.1–12.0 months) than AZT- and d4T-resistance mutations (12.1–24.0 months). Importantly, the prevalence of TAMs increased from 16.7% (1/6) at 12.1–24.0 months to 100% (5/5) at ≧36.1 months. As the accumulation of TAMs confers cross-resistance not only to the first-line NRTIs (AZT, d4T, and 3TC), but also to the second-line NRTIs (ABC, TDF, and ddI) to some extent <xref ref-type="bibr" rid="pone.0071972-Whitcomb1">[18]</xref>, their accumulation should be avoided by conducting drug-resistance testing earlier and appropriately switching the regimen, once virological failure is suspected.</p><p>As no transmitted HIV-1 drug-resistance mutation was found among the 59 newly diagnosed treatment-naïve adult cases, the transmission of drug-resistant HIV-1 appeared to be a rare event in Koforidua, Ghana. Comparing our data with that from other African countries with a similar background, roll-out time of ART, and coverage rate of ART (26.6% in Ghana) <xref ref-type="bibr" rid="pone.0071972-Ghana1">[2]</xref>, the low prevalence of transmitted HIV-1 drug resistance is not surprising and understandable. However, we cannot exclude the possibility of low levels of transmitted HIV-1 drug resistance in our 59 ART-naïve adult cases. The results of our study are limited by using direct sequencing, which may not have been sensitive enough to detect minority drug-resistant variants hidden among the wild-type strains. Indeed, several studies have reported 2- to 3-fold higher prevalence of drug-resistance transmission with ultra-deep sequencing than with direct sequencing <xref ref-type="bibr" rid="pone.0071972-Simen1">[19]</xref>, <xref ref-type="bibr" rid="pone.0071972-Lataillade1">[20]</xref>, which can detect 1% minority populations <xref ref-type="bibr" rid="pone.0071972-Wang1">[21]</xref>. Furthermore, as ultra-deep sequencing can better detect the presence of dual or multiple infections of HIV-1 subtypes compared with direct sequencing <xref ref-type="bibr" rid="pone.0071972-Pacold1">[22]</xref>, <xref ref-type="bibr" rid="pone.0071972-Redd1">[23]</xref>, using such new technology may identify subtypes of 26 URFs.</p><p>Finally, an eventual increase of transmitted drug-resistance cases is anticipated in Ghana as well. Thus, access to HIV-1 genotypic drug-resistance testing should ideally be expanded along with the scale-up of ART programs. In addition, vertical transmission of drug-resistant HIV-1 was found in one of 10 newly-diagnosed treatment-naïve children, suggesting that expanded access to HIV-1 genotypic drug-resistance testing is also needed for programs to prevent mother-to-child transmission in Ghana.</p></sec></body><back><ack><p>We thank the participating patients for their understanding and contributions to our study. We appreciate Mr. George Danquah Damptey, Mr. Samuel Nii-Azumah Morton, Mr. Richard Ansong, and Dr. Agyin Mensah for their help and support. We also thank Ms. Claire Baldwin for her help in preparing the manuscript. We thank the National AIDS Control Programme (NACP) and the Ghana AIDS Commission (GAC) for their support.</p></ack><ref-list><title>References</title><ref id="pone.0071972-UNAIDS1"><label>1</label><mixed-citation publication-type="other">UNAIDS (2011) UNAIDS world AIDS day report 2011. Available: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf">http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf</ext-link> Accessed 29 October 2012.</mixed-citation></ref><ref id="pone.0071972-Ghana1"><label>2</label><mixed-citation publication-type="other">Ghana AIDS Commission (2012) Ghana country AIDS progress report. Available: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_GH_Narrative_Report">http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_GH_Narrative_Report</ext-link>[1].pdf. Accessed 29 October 2012.</mixed-citation></ref><ref id="pone.0071972-National1"><label>3</label><mixed-citation publication-type="other">National HIV/AIDS/STI Control Programme (2008) Guidelines for antiretroviral therapy in Ghana. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/ghana_art.pdf">http://www.who.int/hiv/pub/guidelines/ghana_art.pdf</ext-link> Accessed 29 October 2012.</mixed-citation></ref><ref id="pone.0071972-Frentz1"><label>4</label><mixed-citation publication-type="journal"><name><surname>Frentz</surname><given-names>D</given-names></name>, <name><surname>Boucher</surname><given-names>CAB</given-names></name>, <name><surname>van de Vijver</surname><given-names>DAMC</given-names></name> (<year>2012</year>) <article-title>Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world</article-title>. <source>AIDS Rev</source><volume>14</volume>: <fpage>17</fpage>–<lpage>27</lpage><pub-id pub-id-type="pmid">22297501</pub-id></mixed-citation></ref><ref id="pone.0071972-Sagoe1"><label>5</label><mixed-citation publication-type="journal"><name><surname>Sagoe</surname><given-names>KWC</given-names></name>, <name><surname>Dwidar</surname><given-names>M</given-names></name>, <name><surname>Lartey</surname><given-names>M</given-names></name>, <name><surname>Boamah</surname><given-names>I</given-names></name>, <name><surname>Agyei</surname><given-names>AA</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana</article-title>. <source>J Clin Virol</source><volume>40</volume>: <fpage>163</fpage>–<lpage>167</lpage><pub-id pub-id-type="pmid">17827059</pub-id></mixed-citation></ref><ref id="pone.0071972-Delgado1"><label>6</label><mixed-citation publication-type="journal"><name><surname>Delgado</surname><given-names>E</given-names></name>, <name><surname>Ampofo</surname><given-names>WK</given-names></name>, <name><surname>Sierra</surname><given-names>M</given-names></name>, <name><surname>Torpey</surname><given-names>K</given-names></name>, <name><surname>Pérez-Álvarez</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study</article-title>. <source>J Acquir Immune Defic Syndr</source><volume>48</volume>: <fpage>599</fpage>–<lpage>606</lpage><pub-id pub-id-type="pmid">18645511</pub-id></mixed-citation></ref><ref id="pone.0071972-Ampofo1"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ampofo</surname><given-names>WK</given-names></name> (<year>2009</year>) <article-title>Current status of HIV/AIDS treatment, care and support services in Ghana</article-title>. <source>Ghana Med J</source><volume>43</volume>: <fpage>142</fpage>–<lpage>143</lpage><pub-id pub-id-type="pmid">21326992</pub-id></mixed-citation></ref><ref id="pone.0071972-Barnor1"><label>8</label><mixed-citation publication-type="other">Barnor J, Brandful J, Ampofo W, Yamamoto N, Bonney K, <etal>et al</etal>. (2011) Establishment of in-house quantitative real-time RT-PCR assay for monitoring HIV-1 viral loads and efficacy evaluation of ART in Ghanaian AIDS patients in an urban setting. Abstract CDB346. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17–20 July 2011; Rome, Italy. Available: <ext-link ext-link-type="uri" xlink:href="http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200743770">http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200743770</ext-link> Accessed 29 October 2012.</mixed-citation></ref><ref id="pone.0071972-ChibaMizutani1"><label>9</label><mixed-citation publication-type="journal"><name><surname>Chiba-Mizutani</surname><given-names>T</given-names></name>, <name><surname>Miura</surname><given-names>H</given-names></name>, <name><surname>Matsuda</surname><given-names>M</given-names></name>, <name><surname>Matsuda</surname><given-names>Z</given-names></name>, <name><surname>Yokomaku</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs</article-title>. <source>J Clin Microbiol</source><volume>45</volume>: <fpage>477</fpage>–<lpage>487</lpage><pub-id pub-id-type="pmid">17182760</pub-id></mixed-citation></ref><ref id="pone.0071972-Johnson1"><label>10</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>VA</given-names></name>, <name><surname>Calvez</surname><given-names>V</given-names></name>, <name><surname>Gunthard</surname><given-names>HF</given-names></name>, <name><surname>Paredes</surname><given-names>R</given-names></name>, <name><surname>Pillay</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>2011 update of the drug resistance mutations in HIV-1</article-title>. <source>Top Antivir Med</source><volume>19</volume>: <fpage>156</fpage>–<lpage>164</lpage><pub-id pub-id-type="pmid">22156218</pub-id></mixed-citation></ref><ref id="pone.0071972-Bennett1"><label>11</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>DE</given-names></name>, <name><surname>Camacho</surname><given-names>RJ</given-names></name>, <name><surname>Otelea</surname><given-names>D</given-names></name>, <name><surname>Kuritzkes</surname><given-names>DR</given-names></name>, <name><surname>Fleury</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update</article-title>. <source>PLoS One</source><volume>4</volume>: <fpage>e4724</fpage><pub-id pub-id-type="pmid">19266092</pub-id></mixed-citation></ref><ref id="pone.0071972-Meloni1"><label>12</label><mixed-citation publication-type="journal"><name><surname>Meloni</surname><given-names>ST</given-names></name>, <name><surname>Kim</surname><given-names>B</given-names></name>, <name><surname>Sankalé</surname><given-names>J-L</given-names></name>, <name><surname>Hamel</surname><given-names>DJ</given-names></name>, <name><surname>Tovanabutra</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3</article-title>. <source>J Virol</source><volume>78</volume>: <fpage>12438</fpage>–<lpage>12445</lpage><pub-id pub-id-type="pmid">15507630</pub-id></mixed-citation></ref><ref id="pone.0071972-Vidal1"><label>13</label><mixed-citation publication-type="journal"><name><surname>Vidal</surname><given-names>N</given-names></name>, <name><surname>Mulanga</surname><given-names>C</given-names></name>, <name><surname>Bazepeo</surname><given-names>SE</given-names></name>, <name><surname>Lepira</surname><given-names>F</given-names></name>, <name><surname>Delaporte</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Identification and molecular characterization of subsubtype A4 in Central Africa</article-title>. <source>AIDS Res Hum Retroviruses</source><volume>22</volume>: <fpage>182</fpage>–<lpage>187</lpage><pub-id pub-id-type="pmid">16478401</pub-id></mixed-citation></ref><ref id="pone.0071972-Tamura1"><label>14</label><mixed-citation publication-type="journal"><name><surname>Tamura</surname><given-names>K</given-names></name>, <name><surname>Peterson</surname><given-names>D</given-names></name>, <name><surname>Peterson</surname><given-names>N</given-names></name>, <name><surname>Stecher</surname><given-names>G</given-names></name>, <name><surname>Nei</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods</article-title>. <source>Mol Biol Evol</source><volume>28</volume>: <fpage>2731</fpage>–<lpage>2739</lpage><pub-id pub-id-type="pmid">21546353</pub-id></mixed-citation></ref><ref id="pone.0071972-Lole1"><label>15</label><mixed-citation publication-type="journal"><name><surname>Lole</surname><given-names>KS</given-names></name>, <name><surname>Bollinger</surname><given-names>RC</given-names></name>, <name><surname>Paranjape</surname><given-names>RS</given-names></name>, <name><surname>Gadkari</surname><given-names>D</given-names></name>, <name><surname>Kulkarni</surname><given-names>SS</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination</article-title>. <source>J Virol</source><volume>73</volume>: <fpage>152</fpage>–<lpage>160</lpage><pub-id pub-id-type="pmid">9847317</pub-id></mixed-citation></ref><ref id="pone.0071972-Fischetti1"><label>16</label><mixed-citation publication-type="journal"><name><surname>Fischetti</surname><given-names>L</given-names></name>, <name><surname>Opare-Sem</surname><given-names>O</given-names></name>, <name><surname>Candotti</surname><given-names>D</given-names></name>, <name><surname>Sarkodie</surname><given-names>F</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Molecular epidemiology of HIV in Ghana: dominance of CRF02_AG</article-title>. <source>J Med Virol</source><volume>73</volume>: <fpage>158</fpage>–<lpage>166</lpage><pub-id pub-id-type="pmid">15122787</pub-id></mixed-citation></ref><ref id="pone.0071972-Barth1"><label>17</label><mixed-citation publication-type="journal"><name><surname>Barth</surname><given-names>RE</given-names></name>, <name><surname>van der Loeff</surname><given-names>MFS</given-names></name>, <name><surname>Schuurman</surname><given-names>R</given-names></name>, <name><surname>Hoepelman</surname><given-names>AIM</given-names></name>, <name><surname>Wensing</surname><given-names>AMJ</given-names></name> (<year>2010</year>) <article-title>Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review</article-title>. <source>Lancet Infect Dis</source><volume>10</volume>: <fpage>155</fpage>–<lpage>166</lpage><pub-id pub-id-type="pmid">20185094</pub-id></mixed-citation></ref><ref id="pone.0071972-Whitcomb1"><label>18</label><mixed-citation publication-type="journal"><name><surname>Whitcomb</surname><given-names>JM</given-names></name>, <name><surname>Parkin</surname><given-names>NT</given-names></name>, <name><surname>Chappey</surname><given-names>C</given-names></name>, <name><surname>Hellmann</surname><given-names>NS</given-names></name>, <name><surname>Petropoulos</surname><given-names>CJ</given-names></name> (<year>2003</year>) <article-title>Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates</article-title>. <source>J Infect Dis</source><volume>188</volume>: <fpage>992</fpage>–<lpage>1000</lpage><pub-id pub-id-type="pmid">14513419</pub-id></mixed-citation></ref><ref id="pone.0071972-Simen1"><label>19</label><mixed-citation publication-type="journal"><name><surname>Simen</surname><given-names>BB</given-names></name>, <name><surname>Simons</surname><given-names>JF</given-names></name>, <name><surname>Hullsiek</surname><given-names>KH</given-names></name>, <name><surname>Novak</surname><given-names>RM</given-names></name>, <name><surname>MacArthur</surname><given-names>RD</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes</article-title>. <source>J Infect Dis</source><volume>199</volume>: <fpage>693</fpage>–<lpage>701</lpage><pub-id pub-id-type="pmid">19210162</pub-id></mixed-citation></ref><ref id="pone.0071972-Lataillade1"><label>20</label><mixed-citation publication-type="journal"><name><surname>Lataillade</surname><given-names>M</given-names></name>, <name><surname>Chiarella</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Schnittman</surname><given-names>S</given-names></name>, <name><surname>Wirtz</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study</article-title>. <source>PLoS One</source><volume>5</volume>: <fpage>e10952</fpage><pub-id pub-id-type="pmid">20532178</pub-id></mixed-citation></ref><ref id="pone.0071972-Wang1"><label>21</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Mitsuya</surname><given-names>Y</given-names></name>, <name><surname>Gharizadeh</surname><given-names>B</given-names></name>, <name><surname>Ronaghi</surname><given-names>M</given-names></name>, <name><surname>Shafer</surname><given-names>RW</given-names></name> (<year>2007</year>) <article-title>Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance</article-title>. <source>Genome Res</source><volume>17</volume>: <fpage>1195</fpage>–<lpage>1201</lpage><pub-id pub-id-type="pmid">17600086</pub-id></mixed-citation></ref><ref id="pone.0071972-Pacold1"><label>22</label><mixed-citation publication-type="journal"><name><surname>Pacold</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>D</given-names></name>, <name><surname>Little</surname><given-names>S</given-names></name>, <name><surname>Cheng</surname><given-names>PM</given-names></name>, <name><surname>Jordan</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Comparison of methods to detect HIV dual infection</article-title>. <source>AIDS Res Hum Retroviruses</source><volume>26</volume>: <fpage>1291</fpage>–<lpage>1298</lpage><pub-id pub-id-type="pmid">20954840</pub-id></mixed-citation></ref><ref id="pone.0071972-Redd1"><label>23</label><mixed-citation publication-type="journal"><name><surname>Redd</surname><given-names>AD</given-names></name>, <name><surname>Collinson-Streng</surname><given-names>A</given-names></name>, <name><surname>Martens</surname><given-names>C</given-names></name>, <name><surname>Ricklefs</surname><given-names>S</given-names></name>, <name><surname>Mullis</surname><given-names>CE</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing</article-title>. <source>J Clin Microbiol</source><volume>49</volume>: <fpage>2859</fpage>–<lpage>2867</lpage><pub-id pub-id-type="pmid">21697329</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000486 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000486 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3747072
|texte= HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23977189" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |